Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: Inhibition of CYP2B1 by Oxolamine in male rats

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 3, 2007, Pages 125-133

  Zhu, Xuan ^a,b   Lee, Dae Y ^a   Shin, Wan G ^a  

^a Seoul National University   (South Korea)

^b XIAMEN UNIVERSITY   (China)

Author keywords

CYP2B1; Oxolamine; Pharmacokinetic interaction; Rats; Warfarin

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 1A1; CYTOCHROME P450 2B1; CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; OXOLAMINE CITRATE; PHENYTOIN; TORASEMIDE; WARFARIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; LIVER MICROSOME; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA PROTEIN BINDING; RAT; RAT STRAIN; SEX DIFFERENCE; STATISTICAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; AREA UNDER CURVE; CLARITHROMYCIN; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; MALE; OXADIAZOLES; PHENYTOIN; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SULFONAMIDES; WARFARIN;

EID: 34248354827     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.538     Document Type: Article

References (28)

1. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-239.
2. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
3. Kaminsky LS, Guengerich FP, Dannan GA, Aust DS. Comparisons of warfarin metabolism by liver microsomes of rats treated with a series of polybrominated biphenyl congeners and by the component-purified cytochrome P450 isozymes. Arch Biochem Biophys 1983; 225: 398-404.
4. Lewis DFV. P450. Substrate specificity and metabolism. In Cytochromes P450. Structure, Function and Mechanism, Lewis DFV (ed.). Taylor & Francis: Bristol, 1996; 122-123.
5. Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn, Brunton LL, Lazo JS, Parker KL (eds). McGraw-Hill, Medical Publishing Division: New York, 2006.
6. Zhu X, Shin WG. Gender differences in pharmacokinetics of oral warfarin in rats. Biopharm Drug Dispos 2005; 26: 147-150.
7. Min KA, Zhu X, Oh JM, Shin WG. Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm 2006; 63: 153-156.
8. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127-132.
9. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
10. Chan K, Lo AC, Yeung JH, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 1995; 47: 402-406.
11. Kim YG, Cho MK, Kwon JW, et al. Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. Int J Pharm 2001; 229: 45-55.
12. Bae SK, Lee DY, Lee AK, et al. Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. J Pharm Sci 2004; 93: 2388-2398.
13. Lee AK, Lee JH, Kwon JW, et al. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 2004; 25: 273-282.
14. Kim YC, Kwon JW, Kim WB, Lee I, Lee MG. Pharmacokinetic changes of intravenous DA-8159, a new erectogenic, in rats with diabetes mellitus induced by streptozotocin. J Pharm Sci 2004; 93: 2374-2387.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
16. Tanaka E, Sakamoto N, Inubushi M, Misawa S. Simultaneous determination of plasma phenytoin and its primary hydroxylated metabolites in carbon tetrachloride-intoxicated rats by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 673: 147-151.
17. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.
18. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
19. Chu SY, Sennello LT, Sonders RC. Simultaneous determination of clarithromycin and 14R-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 571: 199-208.
20. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
21. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker: New York; 1982.
22. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
23. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
24. Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 1980; 69: 90-91.
25. Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm 1985; 13: 477-492.
26. Yamazaki H, Komatsu T, Takemoto K, et al. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos 2001; 29: 427-434.
27. Billings RE. Interactions between folate metabolism, phenytoin metabolism, and liver microsomal cytochrome P450. Drug Nutr Interact 1984; 3: 21-32.
28. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209.